

Please replace the paragraph encompassed by page 3, lines 5-18, with the following

paragraph:

Sub
E2
B2

Regarding the neuroprotective effect of compounds having mGluR1 antagonism in cerebral ischemia, Cozzi et al. reported that intraventricular administration of AIDA ((RS)-1-aminoindan-1,5-dicarboxylic acid) reduced the loss of the neuronal cells found in the CA1 area of gerbils exposed to 5 min of cerebral ischemia (Society for Neuroscience Abstracts, vol. 23, 788.2, 1997). However, Henrich-Noack et al. reported that 4C3HPG ((S)-4-carboxy-3-hydroxyphenylglycine), which is an antagonist of the Group I mGluRs and an agonist of Group II mGluRs, is effective, but 4CPG ((S)-4-carboxyphenylglycine), which is a selective Group I mGluR antagonist is not effective in the same model (Society for Neuroscience Abstracts, vol. 23, 756.8, 1997).

Please replace the paragraph encompassed by page 3, lines 19-25, with the following

paragraph:

Sub
B3

One of the reasons for this discrepancy is considered to be due to the insufficient efficacy and selectivity of mGluR1 antagonists used in these experiments. Therefore, it is considered that the neuroprotective effect of compounds having mGluR1 antagonism in cerebral ischemia is not clearly confirmed.

Please replace the paragraph encompassed by page 19, lines 22-24, with the

following paragraph:

B4 Sub
B3

Next, the invention is described further in detail based on examples, though the invention is not limited to these examples.